REV-MED has signed an export agreement with Spain-based REMECO for its autologous stem cell therapy bio-kit, TriCell. The contract is valued at $1.35 million, with a potential increase to $1.75 million, spanning a three-year period.
Since dissolving its German subsidiary in 2021, REV-MED has been pursuing direct entry into the European market. This agreement with REMECO marks a significant step in expanding its presence in Europe.
During the contract period, REV-MED will collaborate with REMECO to promote the autologous stem cell therapy market in Spain through seminars, participation in exhibitions, and academic publications.
CEO Bongkeun Shin stated, “After significant efforts to enter the European market, we are beginning to see tangible results. Starting with Spain, we aim to finalize ongoing deals with Greece, Bulgaria, and Italy to solidify our presence in Europe.”
Founded in 2009, REV-MED specializes in developing cell regeneration therapy systems using autologous stem cells and laser-based medical devices. The company currently exports its products to over 20 countries, including China, Japan, Southeast Asia, the Middle East, and Europe.
Source : HealthTrends (http://www.k-health.com)
REV-MED has signed an export agreement with Spain-based REMECO for its autologous stem cell therapy bio-kit, TriCell. The contract is valued at $1.35 million, with a potential increase to $1.75 million, spanning a three-year period.
Since dissolving its German subsidiary in 2021, REV-MED has been pursuing direct entry into the European market. This agreement with REMECO marks a significant step in expanding its presence in Europe.
During the contract period, REV-MED will collaborate with REMECO to promote the autologous stem cell therapy market in Spain through seminars, participation in exhibitions, and academic publications.
CEO Bongkeun Shin stated, “After significant efforts to enter the European market, we are beginning to see tangible results. Starting with Spain, we aim to finalize ongoing deals with Greece, Bulgaria, and Italy to solidify our presence in Europe.”
Founded in 2009, REV-MED specializes in developing cell regeneration therapy systems using autologous stem cells and laser-based medical devices. The company currently exports its products to over 20 countries, including China, Japan, Southeast Asia, the Middle East, and Europe.
Source : HealthTrends (http://www.k-health.com)